Remington College Nashville Campus begins enrollment for new pharmacy tech program
NASHVILLE, Tenn. — Remington College Nashville Campus has started the process of enrolling students for its new Pharmacy Technician diploma program. The program incorporates a realistic pharmacy environment and a hands-on curriculum to help prepare students interested in pursuing entry-level jobs in the pharmacy field.
The program, which can be completed in as few as 13 months, includes such courses as pharmacy practice; law, ethics and therapeutic communication; dosage calculation; therapeutics, prescription entry and billing; sterile products and quality assurance; and extemporaneous compounding and inventory management.
"We are very pleased to be able to offer the Pharmacy Technician program to students in the Nashville area," said James Saulsbury, Remington College Nashville Campus president. "Pharmacy technicians will be in demand everywhere from commercial pharmacies to hospitals."
The demand for health services is expected to create a favorable job outlook for pharmacy technicians for several years, the school said, citing projected growth figures from the Bureau of Labor Statistics.
All graduates from the program will hold two certifications: the Sterile Products Certification and the Pharmacy Technician Certification.
P&G sees Q3 organic sales climb 3%
CINCINNATI — Procter & Gamble announced on Wednesday that third-quarter results met expectations, and the company remains on track to deliver top- and bottom-line growth objectives for the fiscal year.
Net sales for the quarter remained flat at $20.6 billion, including a negative three-percentage point impact from foreign exchange. P&G delivered organic sales growth of 3% for the quarter.
Fiscal year 2014 core earnings per share were $1.04, an increase of 5% versus the prior year. On a currency-neutral basis, core earnings per share increased 17% for the quarter. Diluted net earnings per share were 90 cents, an increase of 2%.
“We’re operating in a slow-growth, highly competitive environment, which places even greater importance on strong innovation and productivity improvement. We’re delivering meaningful product innovations that are attracting more consumers to our brands. We’re making good progress on our productivity plans, with cost savings and enrollment reductions ahead of going-in targets for the year. We’re confident that the cumulative benefits from these innovations and productivity improvements will lead, over time, to improved value creation for consumers, customers and shareholders,” said chairman, president and CEO A.G. Lafley.
In the beauty segment, organic sales increased 2% from innovation in hair care, deodorants and personal cleansing, and market growth. This was partially offset by a sales decrease in salon professional and skin care primarily in Asia.
In grooming, organic sales increased 1% due to higher pricing and innovation on blades and razors and appliances, which was partially offset by geographic and product mix and market contraction in developed regions.
Bayer HealthCare gains orphan drug designation for investigational Ciprofloxacin Dry Powder
WHIPPANY, N.J. — Bayer HealthCare on Tuesday announced that the Food and Drug Administration’s Office of Orphan Products Development has granted orphan drug designation for Bayer’s investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) for the treatment of non-cystic fibrosis bronchiectasis. Patients with NCFB suffer from frequent severe acute pulmonary bacterial exacerbations, which lead to further inflammation, airway and lung parenchyma damage.
The Orphan Drug Designation program provides orphan status to drugs and biologics that are intended for the safe and effective treatment, diagnosis or prevention of rare diseases and disorders that affect fewer than 200,000 people in the United States, or that affect more than 200,000 but are not expected to recover the costs of developing and marketing a treatment drug.
Ciprofloxacin DPI is in development by Bayer HealthCare as chronic intermittent therapy for reducing the frequency of acute exacerbations in NCFB patients with bacterial respiratory pathogens. It comprises ciprofloxacin, a fluoroquinolone antibiotic, formulated into dry powder for inhalation using Novartis’ PulmoSphere technology and is administered with the T-326 Dry Powder inhaler. Ciprofloxacin DPI therapy in NCFB currently is being investigated in a global Phase III clinical trial program.